Thus, although Egr2 might be a target for liver fibrosis in MASH, Egr2 should be targeted selectively in monocytes and macrophages in order not to inhibit protective responses by LAG3+CD4+CD25- regulatory T cells. The gene discussed is CD4; the disease is metabolic dysfunction-associated steatohepatitis.